SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.
IPO Year: 2021
Exchange: NASDAQ
Website: sabbiotherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $10.00 | Buy | H.C. Wainwright |
| 10/9/2024 | $11.00 | Buy | Craig Hallum |
| 8/28/2024 | $12.00 | Outperform | Oppenheimer |
| 11/5/2021 | $17.00 | Buy | Chardan Capital Markets |
| 11/2/2021 | $23.00 | Outperform | Robert W. Baird |
| 11/2/2021 | $23.00 | Outperform | Baird |